Back to Search
Start Over
Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial
- Source :
- Journal of cancer research and clinical oncology. 137(9)
- Publication Year :
- 2011
-
Abstract
- To present an updated survival analysis of an open-label, parallel-group, phase IIB trial of BLP25 liposome vaccine (L-BLP25) in patients with stage IIIB or IV non-small-cell lung cancer (NSCLC). Patients were randomized to either L-BLP25 plus best supportive care (BSC) or BSC alone. Patients in the L-BLP25 arm received subcutaneous vaccinations of L-BLP25 930 μg weekly for 8 weeks, followed by maintenance vaccinations at 6-week intervals. Median survival time was 4.2 months longer in patients receiving L-BLP25 plus BSC (n = 88) than in those receiving BSC alone (n = 83; 17.2 months vs. 13.0 months, respectively; hazard ratio [HR] 0.745, 95% confidence interval [CI] 0.533–1.042). The 3-year survival rate was 31% in patients receiving L-BLP25 plus BSC and 17% in those receiving BSC (P = 0.035). In the stratified subset of patients with stage IIIB loco-regional (LR) disease, median survival time was 17.3 months longer in patients receiving L-BLP25 plus BSC (n = 35) than in those receiving BSC (n = 30; 30.6 months vs. 13.3 months, respectively; HR 0.548, 95% CI 0.301–0.999). In this subgroup, 3-year survival was 49% in patients receiving L-BLP25 plus BSC and 27% in those receiving BSC (P = 0.070). Confirming the initial results, further follow-up continues to show that survival time for patients with stage IIIB/IV NSCLC was longer with L-BLP25 plus BSC compared with BSC alone, with the greatest difference seen in patients with stage IIIB LR disease.
- Subjects :
- Male
Cancer Research
medicine.medical_specialty
Randomization
Lung Neoplasms
viruses
Cancer Vaccines
law.invention
Randomized controlled trial
law
Internal medicine
Carcinoma, Non-Small-Cell Lung
Carcinoma
medicine
Humans
Lung cancer
Survival rate
Survival analysis
Neoplasm Staging
Membrane Glycoproteins
urogenital system
business.industry
Hazard ratio
General Medicine
biochemical phenomena, metabolism, and nutrition
Middle Aged
medicine.disease
Survival Analysis
Confidence interval
Surgery
Survival Rate
Oncology
Liposomes
Female
Immunotherapy
business
Subjects
Details
- ISSN :
- 14321335
- Volume :
- 137
- Issue :
- 9
- Database :
- OpenAIRE
- Journal :
- Journal of cancer research and clinical oncology
- Accession number :
- edsair.doi.dedup.....9e5b4faa9eeabe0c7629acd62290c003